Published in J Vis Exp on September 29, 2014
Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system. Psychopharmacology (Berl) (2015) 0.81
Angiotensin type 1a receptors on corticotropin-releasing factor neurons contribute to the expression of conditioned fear. Genes Brain Behav (2015) 0.79
Maternal cortisol stimulates neurogenesis and affects larval behaviour in zebrafish. Sci Rep (2017) 0.77
Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget (2016) 0.77
Neuroprotective effect of WIN55,212-2 against 3-nitropropionic acid-induced toxicity in the rat brain: involvement of CB1 and NMDA receptors. Am J Transl Res (2017) 0.75
Suite of Clinically Relevant Functional Assays to Address Therapeutic Efficacy and Disease Mechanism in the Dystrophic mdx Mouse. J Appl Physiol (1985) (2016) 0.75
Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice. Microbiome (2017) 0.75
Edaravone reduces astrogliosis and apoptosis in young rats with kaolin-induced hydrocephalus. Childs Nerv Syst (2016) 0.75
MR brain volumetric measurements are predictive of neurobehavioral impairment in the HIV-1 transgenic rat. Neuroimage Clin (2017) 0.75
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol (2003) 6.40
Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27
The Open-Field Test: a critical review. Psychol Bull (1976) 3.59
Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res (2001) 2.98
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis (2008) 2.20
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A (2000) 2.13
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol Ther (2010) 1.48
Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS One (2012) 1.10
Differentiation of presumed serotonergic dorsal raphe neurons in relation to behavior and wake-sleep states. Neuroscience (2001) 1.09
Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther (2009) 1.06
Effects of strain, sex, and illumination on open-field behavior of rats. Am J Psychol (1970) 1.05
Aged rats: sex differences and responses to chronic stress. Brain Res (2006) 1.03
Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One (2010) 1.01
Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul Disord (2000) 1.00
Evaluation of Lewis and SHR rat strains as a genetic model for the study of anxiety and pain. Behav Brain Res (2002) 0.95
Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies. Neuromuscul Disord (2011) 0.92
Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One (2013) 0.85